CAS 2095393-15-8

ARQ 531

CAS : 2095393-15-8

ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.

Formule : C₂₅H₂₃ClN₄O₄

Degré de pureté : 98.68% - 99.63%

Couleur et forme : Solid

Masse moléculaire : 478.93

Ref: TM-T14323

1,​5-​Anhydro-​2-​[[5-​(2-​chloro-​4-​phenoxybenzoyl)​-​7H-​pyrrolo[2,​3-​d]​pyrimidin-​4-​yl]​amino]​-​2,​3,​4-​trideoxy-​D-​erythro-​hexitol

CAS : 2095393-15-8

Formule : C₂₅H₂₃ClN₄O₄

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 478.9275

Ref: IN-DA01EO8E

ARQ 531

CAS : 2095393-15-8

ARQ 531

Degré de pureté : ≥98%

Masse moléculaire : 478.93g/mol

Ref: 54-BUP09823

ARQ 531

Produit contrôlé

CAS : 2095393-15-8

Formule : C₂₅H₂₃ClN₄O₄

Couleur et forme : Neat

Masse moléculaire : 478.928

Ref: TR-A158920

ARQ 531

CAS : 2095393-15-8

ARQ 531 is a small molecule inhibitor specifically designed to target Bruton's tyrosine kinase (BTK), which is a type of enzymatic protein. This compound is meticulously developed within a laboratory setting to disrupt key pathways involved in cancer cell survival. Its mode of action involves the selective and reversible inhibition of BTK, thereby obstructing signal transduction that promotes malignant cell proliferation and survival.

Formule : C₂₅H₂₃ClN₄O₄

Degré de pureté : Min. 95%

Masse moléculaire : 478.93 g/mol

Ref: 3D-VID39315